Accelerating cell therapy discovery & development with non-viral gene engineering

David is the Senior Manager of R&D Applications in Cell and Gene Therapy at Bio-Techne. He works with Bio-Techne’s suite of cell and gene therapy products to establish appropriate protocols and workflows for the modification of immune cells include CAR T and CAR NK cell workflows. His career has focused on non-viral gene editing of T and NK cells using transposon systems and continues to drive the adoption of TcBuster™ for cell therapy.

Xiaobai Patrinostro is the Manager of Genome Engineering Services in Cell and Gene Therapy at BioTechne. Xiaobai received her PhD in Molecular Biology and Biochemistry from the University of Minnesota. Xiaobai has 18 years of experience in biological sciences, 10 of which in genome engineering. Xiaobai joined BMogen BioTechnologies in 2018 which was acquired by BioTechne in 2019. Xiaobai’s work at BioTechne is focused on utilizing the TcBuster™ technology to engineer custom cell lines for clients in the Cell and Gene therapy field.

Scott Silaika has over 20 years of business development experience in drug development and manufacturing services, spanning from discovery through commercial, within the contract development and manufacturing (CDMO) industry. Scott’s experience includes numerous examples of identifying, leading, and supporting customer projects on high profile, mission-critical initiatives.Prior to joining Bio-Techne, Mr. Silaika held commercial development positions at AbbVie, Aesica, Albany Molecular, Avara, and Ricerca Biosciences. He earned his undergraduate degree in Chemical Engineering from Rensselaer Polytechnic Institute and his MBA from the State University at Albany.